HER21 breast cancer therapy: By CPP-ZFN mediated targeting of mTOR?

Technology in Cancer Research and Treatment

Volumn 11, Issue 2, 2012, Pages 175-180

  Puria, Rekha ^a   Sahi, Shakti ^a   Nain, Vikrant ^a  

^a GAUTAM BUDDHA UNIVERSITY   (India)

Author keywords

Drug delivery; Drug resistance; Gene therapy; Molecular scissors; Trastuzumab

Indexed keywords

CELL PENETRATING PEPTIDE; CHEMOKINE RECEPTOR CCR5; EPIDERMAL GROWTH FACTOR RECEPTOR 2; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; RAPAMYCIN; TRASTUZUMAB; VASCULOTROPIN A; Y BOX BINDING PROTEIN 1; ZINC FINGER NUCLEASE; ANTINEOPLASTIC AGENT; DEOXYRIBONUCLEASE; DNA; ERBB2 PROTEIN, HUMAN; MONOCLONAL ANTIBODY; MTOR PROTEIN, HUMAN; TARGET OF RAPAMYCIN KINASE; ZINC FINGER PROTEIN;

ARTICLE; BREAST CANCER; CANCER THERAPY; GENE EXPRESSION; GENOME; HUMAN; SIGNAL TRANSDUCTION; VALIDATION PROCESS; DNA METHYLATION; DRUG TARGETING; MOLECULAR DYNAMICS; PROSTATE CANCER; PROTEIN DNA INTERACTION; PROTEIN PHOSPHORYLATION; SEQUENCE ANALYSIS; ANTAGONISTS AND INHIBITORS; BREAST NEOPLASMS; DRUG RESISTANCE; FEMALE; GENE TARGETING; METABOLISM;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL-PENETRATING PEPTIDES; DEOXYRIBONUCLEASES; DNA; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE TARGETING; HUMANS; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR, ERBB-2; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES; ZINC FINGERS;

EID: 84877733350     PISSN: 15330346     EISSN: None     Source Type: Journal    
DOI: 10.7785/tcrt.2012.500247     Document Type: Article

References (49)

1. Jones, K. L., Buzdar, A. U. Evolving novel anti-HER2 strategies. Lancet Oncol 10, 1179-1187 (2009).[Crossref]
2. Nahta, R., Esteva, F. HER2 therapy: Molecular mechanisms of trastuzumab resistance. Breast Cancer Res 8, 215-223 (2006).
3. Nahta, R., O'Regan, R. Evolving Strategies for Overcoming Resistance to HER2-Directed Therapy: Targeting the PI3K/Akt/mTOR Pathway. Clin Breast Cancer 10, S72-S78 (2010). [Crossref]
4. Baselga, J. Targeting the Phosphoinositide-3 (PI3) Kinase Pathway in Breast Cancer. The Oncologist 16, 12-19 (2011). [Crossref]
5. Carraway, H., Hidalgo, M. New targets for therapy in breast cancer: Mammalian target of rapamycin (mTOR) antagonists. Breast Cancer Res 6, 219-224 (2004).
6. Freudenberg, J. A., Wang, Q., Katsumata, M., Drebin, J., Nagatomo, I., Greene, M. I. The role of HER2 in early breast cancer metastasis and the origins of resistance to HER2-targeted therapies. Exp Mol Pathol 87, 1-11 (2009). [Crossref]
7. Morrow, P. K., Wulf, G. M., Ensor, J., Booser, D. J., Moore, J. A., Flores, P. R., Xiong, Y., Zhang, S., Krop, I. E., Winer, E. P., Kindelberger, D. W., Coviello, J., Sahin, A. A., Nuñez, R., Hortobagyi, G. N., Yu, D., Esteva, F. J. Phase I/II Study of Trastuzumab in Combination With Everolimus (RAD001) in Patients With HER2-Overexpressing Metastatic Breast Cancer Who Progressed on Trastuzumab-Based Therapy. J Clin Oncol 29, 3126-3132 (2011). [Cross[Crossref]ref]
8. Puria, R., Zurita-Martinez, S. A., Cardenas, M. E. Nuclear translocation of Gln3 in response to nutrient signals requires Golgi-to-endosome trafficking in Saccharomyces cerevisiae. Proc Natl Acad Sci 105, 7194-7199 (2008). [Crossref]
9. Thoreen, C. C., Sabatini, D. M. Rapamycin inhibits mTORC1, but not completely. Autophagy 5, 725-726 (2009). [Crossref]
10. Miller, T. W., Forbes, J. T., Shah, C., Wyatt, S. K., Manning, H. C., Olivares, M. G., Sanchez, V., Dugger, T. C., de Matos Granja, N., Narasanna, A., Cook, R. S., Kennedy, J. P., Lindsley, C. W., Arteaga, C. L. Inhibition of Mammalian Target of Rapamycin Is Required for Optimal Antitumor Effect of HER2 Inhibitors against HER2-Overexpressing Cancer Cells. Clinical Cancer Res 15, 7266-7276 (2009).[Crossref]
11. Cradick, T. J., Keck, K., Bradshaw, S., Jamieson, A. C., McCaffrey, A. P. Zinc-finger Nucleases as a Novel Therapeutic Strategy for Targeting Hepatitis B Virus DNAs. Mol Ther 18, 947-954 (2010). [Crossref]
12. Kandavelou, K., Chandrasegaran, S. Custom-designed molecular scissors for site-specific manipulation of the plant and mammalian genomes. Methods Mol Biol 544, 617-636 (2009). [Crossref]
13. Lee, H. J., Kim, E., Kim, J.-S. Targeted chromosomal deletions in human cells using zinc finger nucleases. Genome Res 20, 81-89 (2010). [Crossref]
14. Remy, S., Tesson, L., Menoret, S., Usal, C., Scharenberg, A. M., Anegon, I., Santiago, Y., Chan, E., Liu, P. Q., Orlando, S., Zhang, L., Urnov, F. D., Holmes, M. C., Guschin, D., Waite, A., Miller, J. C., Rebar, E. J., Gregory, P. D., Klug, A., Collingwood, T. N., Wu, J., Kandavelou, K., Chandrasegaran, S., Mani, M., Kandavelou, K., Dy, F. J., Durai, S., Chandrasegaran, S. Zinc-finger nucleases: a powerful tool for genetic engineering of animals. Transgenic Res 19, 363-371 (2009). [Crossref]
15. Sollu, C., Pars, K., Cornu, T. I., Thibodeau-Beganny, S., Maeder, M. L., Joung, J. K., Heilbronn, R., Cathomen, T. Autonomous zinc-finger nuclease pairs for targeted chromosomal deletion. Nucl Acids Res 38, 8269-8276 (2010) [Crossref].
16. Mani, M., Kandavelou, K., Dy, F. J., Durai, S., Chandrasegaran, S. Design, engineering, and characterization of zinc finger nucleases. Biochem Biophys Res Commun 335, 447-457 (2005).[Crossref]
17. Kandavelou, K., Chandrasegaran, S., Kandavelou, K., Ramalingam, S., London, V., Mani, M., Wu, J., Alexeev, V., Civin, C. I., Chandrasegaran, S., Lee, H. J., Kim, E., Kim, J. S. Custom-designed molecular scissors for site-specific manipulation of the plant and mammalian genomes. Methods Mol Biol 544, 617-636 (2009). [Crossref]
18. Shukla, V. K., Doyon, Y., Miller, J. C., DeKelver, R. C., Moehle, E. A., Worden, S. E., Mitchell, J. C., Arnold, N. L., Gopalan, S., Meng, X., Choi, V. M., Rock, J. M., Wu, Y. Y., Katibah, G. E., Zhifang, G., McCaskill, D., Simpson, M. A., Blakeslee, B., Greenwalt, S. A., Butler, H. J., Hinkley, S. J., Zhang, L., Rebar, E. J., Gregory, P. D., Urnov, F. D. Precise genome modification in the crop species Zea mays using zinc-finger nucleases. Nature 459, 437-441 (2009). [Crossref]
19. Foley, J. E., Yeh, J. R., Maeder, M. L., Reyon, D., Sander, J. D., Peterson, R. T., Joung, J. K. Rapid mutation of endogenous zebrafish genes using zinc finger nucleases made by Oligomerized Pool ENgineering (OPEN). PLoS One 4, e4348 (2009). [Crossref]
20. Kumar, S., Allen, G. C., Thompson, W. F. Gene targeting in plants: fingers on the move. Trends Plant Sci 11, 159-161 (2006). [Crossref]
21. Beumer, K., Bhattacharyya, G., Bibikova, M., Trautman, J. K., Carroll, D. Efficient Gene Targeting in Drosophila With Zinc-Finger Nucleases. Genetics 172, 2391-2403 (2006). [Crossref]
22. Davis, D., Stokoe, D. Zinc Finger Nucleases as tools to understand and treat human diseases. BMC Medicine 8, 42 (2010). [Crossref]
23. Nain, V., Sahi, S., Verma, A. CPP-ZFN: a potential DNA-targeting anti-malarial drug. Malar J 9, 258 (2010). [Crossref]
24. Holt, N., Wang, J., Kim, K., Friedman, G., Wang, X., Taupin, V., Crooks, G. M., Kohn, D. B., Gregory, P. D., Holmes, M. C., Cannon, P. M. Human hematopoietic stem/progenitor cells modified by zinc-finger nucleases targeted to CCR5 control HIV-1 in vivo. Nat Biotechnol 28, 839-847 (2010). [Crossref]
25. Perez, E. E., Wang, J., Miller, J. C., Jouvenot, Y., Kim, K. A., Liu, O., Wang, N., Lee, G., Bartsevich, V. V., Lee, Y. L., Guschin, D. Y., Rupniewski, I., Waite, A. J., Carpenito, C., Carroll, R. G., Orange, J. S., Urnov, F. D., Rebar, E. J., Ando, D., Gregory, P. D., Riley, J. L., Holmes, M. C., June, C. H. Establishment of HIV-1 resistance in CD41 T cells by genome editing using zinc-finger nucleases. Nat Biotechnol 26, 808-816 (2008).
26. Herrmann, F., Garriga-Canut, M., Baumstark, R., Fajardo-Sanchez, E., Cotterell, J., Minoche, A., Himmelbauer, H., Isalan, M. p53 Gene Repair with Zinc Finger Nucleases Optimised by Yeast 1-Hybrid and Validated by Solexa Sequencing. PLoS ONE 6, e20913 (2011). [Crossref]
27. Ji, P., Diederichs, S., Wang, W., Boing, S., Metzger, R., Schneider, P. M., Tidow, N., Brandt, B., Buerger, H., Bulk, E., Thomas, M., Berdel, W. E., Serve, H., Muller-Tidow, C. MALAT-1, a novel noncoding RNA, and thymosin [beta]4 predict metastasis and survival in early-stage non-small cell lung cancer. Oncogene 22, 8031-8041 (2011)
28. Maeder, M. L., Thibodeau-Beganny, S., Osiak, A., Wright, D. A., Anthony, R. M., Eichtinger, M., Jiang, T., Foley, J. E., Winfrey, R. J., Townsend, J. A., Unger-Wallace, E., Sander, J. D., Muller-Lerch, F., Fu, F., Pearlberg, J., Gobel, C., Dassie, J. P., Pruett-Miller, S. M., Porteus, M. H., Sgroi, D. C., Iafrate, A. J., Dobbs, D., McCray, P. B., Jr., Cathomen, T., Voytas, D. F., Joung, J. K. Rapid "open-source" engineering of customized zinc-finger nucleases for highly efficient gene modification. Mol Cell 31, 294-301 (2008).[Crossref]
29. Sander, J. D., Zaback, P., Joung, J. K., Voytas, D. F., Dobbs, D. Zinc Finger Targeter (ZiFiT): an engineered zinc finger/target site design tool. Nucleic Acids Res 35, W599-605 (2007). [Crossref]
30. Mandell, J. G., Barbas, C. F., 3rd Zinc Finger Tools: custom DNA-binding domains for transcription factors and nucleases. Nucleic Acids Res 34, W516-523 (2006). [Crossref]
31. Cornu, T. I., Cathomen, T. Quantification of zinc finger nuclease-associated toxicity. Methods Mol Biol 649, 237-245 (2010). [Crossref]
32. Pattanayak, V., Ramirez, C. L., Joung, J. K., Liu, D. R. Revealing off-target cleavage specificities of zinc-finger nucleases by in vitro selection. Nat Meth 8, 765-770 (2011). [Crossref]
33. Doyon, Y., Vo, T. D., Mendel, M. C., Greenberg, S. G., Wang, J., Xia, D. F., Miller, J. C., Urnov, F. D., Gregory, P. D., Holmes, M. C. Enhancing zinc-finger-nuclease activity with improved obligate heterodimeric architectures. Nat Meth 8, 74-79 (2010). [Crossref]
34. Ramalingam, S., Kandavelou, K., Rajenderan, R., Chandrasegaran, S. Creating Designed Zinc-Finger Nucleases with Minimal Cytotoxicity. Journal of Molecular Biology 405, 630-641 (2011). [Crossref]
35. Shimizu, Y., Söllü, C., Meckler, J. F., Adriaenssens, A., Zykovich, A., Cathomen, T., Segal, D. J. Adding Fingers to an Engineered Zinc Finger Nuclease Can Reduce Activity. Biochem 50, 5033-5041 (2011).
36. Seeliger, D., Buelens, F. P., Goette, M., de Groot, B. L., Grubmüller, H. Towards computional specificity screening of DNA-binding proteins. Nucleic Acids Res 39, 8281-8290 (2011). [Crossref]
37. Reyon, D., Kirkpatrick, J., Sander, J., Zhang, F., Voytas, D., Joung, J. K., Dobbs, D., Coffman, C. ZFNGenome: A comprehensive resource for locating zinc finger nuclease target sites in model organisms. BMC Genomics 12, 83 (2011). [Crossref]
38. Bhoumik, A., Gangi, L., Ronai, Z. e. Inhibition of Melanoma Growth and Metastasis by ATF2-Derived Peptides. Cancer Res 64, 8222-8230 (2004). [Crossref]
39. Gupta, B., Levchenko, T. S., Torchilin, V. P. Intracellular delivery of large molecules and small particles by cell-penetrating proteins and peptides. Adv Drug Delivery Rev 57, 637-651 (2005). [Crossref]
40. Järver, P., Langel, Ü. The use of cell-penetrating peptides as a tool for gene regulation. Drug Discov Today 9, 395-402 (2004). [Crossref]
41. Wadia, J. S., Dowdy, S. F. Transmembrane delivery of protein and peptide drugs by TAT-mediated transduction in the treatment of cancer. Adv Drug Delivery Rev 57, 579-596 (2005). [Crossref]
42. Vyas, P. M., Payne, R. M. TAT opens the door. Mol Ther 16, 647-648 (2008). [Crossref]
43. Schwarze, S. R., Ho, A., Vocero-Akbani, A., Dowdy, S. F. In Vivo Protein Transduction: Delivery of a Biologically Active Protein into the Mouse. Science 285, 1569-1572 (1999).
44. Habibi, G., Leung, S., Law, J., Gelmon, K., Masoudi, H., Turbin, D., Pollak, M., Nielsen, T., Huntsman, D., Dunn, S. Redefining prognostic factors for breast cancer: YB-1 is a stronger predictor of relapse and disease-specific survival than estrogen receptor or HER-2 across all tumor subtypes. Breast Cancer Res 10, R86 (2008). [Crossref]
45. Law, J. H., Li, Y., To, K., Wang, M., Astanehe, A., Lambie, K., Dhillon, J., Jones, S. J., Gleave, M. E., Eaves, C. J., Dunn, S. E. Molecular decoy to the Y-box binding protein-1 suppresses the growth of breast and prostate cancer cells whilst sparing normal cell viability. PloS one 5, e12661 (2010). [Crossref]
46. Stratford, A., Fry, C., Desilets, C., Davies, A., Cho, Y., Li, Y., Dong, Z., Berquin, I., Roux, P., Dunn, S. Y-box binding protein-1 serine 102 is a downstream target of p90 ribosomal S6 kinase in basal-like breast cancer cells. Breast Cancer Res 10, R99 (2008). [Crossref]
47. Tan, M., Lan, K.-H., Yao, J., Lu, C.-H., Sun, M., Neal, C. L., Lu, J., Yu, D. Selective Inhibition of ErbB2-Overexpressing Breast Cancer In vivo by a Novel TAT-Based ErbB2-Targeting Signal Transducers and Activators of Transcription 3-Blocking Peptide. Cancer Res 66, 3764-3772 (2006). [Crossref]
48. Janes, M. R., Fruman, D. A. Targeting TOR dependence in cancer. Oncotarget 1, 69-76 (2010).
49. Zoncu, R., Efeyan, A., Sabatini, D. M. mTOR: from growth signal integration to cancer, diabetes and ageing. Nat Rev Mol Cell Biol 12, 21-35 (2011)